The TherapeuticsMD Inc. (NASDAQ:TXMD) is going down by -1.16% in today’s trading session, a fall equivalent to -0.03% of the stock’s price from yesterday’s market close. A news came out on 11/26/19 stating that Knight and TherapeuticsMD Announce Filing of New Drug Submission for BIJUVA(R) in Canada by WSJ. The lowest point that the shares touched during the trading session was $2.40, while the peak of the day was recorded at a share price of $2.57. TXMD finished the previous session at $2.42 according to the data provided by Barchart, while the trading volume was observed to be $1447840.

In the 100 days of trading, TXMD managed to top a 2.96% Moving average. Additionally, TherapeuticsMD Inc. shares have achieved a 52-week range between 1.82 and 6.09 alongside 100 days raw stochastic set at 23.00%.

The number of shares outstanding, according to the fundamentals of the company, is set at 269.00M, equal to the value of $650.98M in market capitalization. In the last 30 days, TherapeuticsMD Inc. shares went down by -19.09%, adding 2.96 to growth in value, on top of a +5.04% boost since 11/01/19.

TherapeuticsMD Inc. (NASDAQ:TXMD) Analyst’s Estimates

TherapeuticsMD Inc. (TXMD) could record at least -$0.19 per share in quarterly earnings in the upcoming report on 02/24/2020, a number that would actually represent a decrease of -0.49 YOY.

According to the average analyst rating, TherapeuticsMD Inc. would be rated as Buy. Out of 8 different analysts monitoring TXMD stock, 7 analysts rate the stock as a BUY, 1 suggest to give the rating of HOLD, 0 indicate that TXMD is an OVERWEIGHT, 0 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERWEIGHT.

On December 02, 2019, the stock earned a Initiated rating due to a new analyst call from Guggenheim, while analysts from H.C. Wainwright believe that the stock is set at Buy, as concluded on October 17, 2019. Noble Capital Markets, is still rather wary about the stock, deciding to keep the rating at Outperform as confirmed through a call on April 30, 2019.

Regardless of the rating, JP Morgan did increase their price to $11 as they are considering target share price analysis. Morgan Stanley, on the other hand, provided a rather enthusiastic opinion on the rating, concluded in an analyst call on September 08, 2017, giving the stock a Equal-Weight rating.

TXMD Key Ratios To Watch:

Taking in account the profitability of the Company, gross profit margin of +81.17% has been attained, while the operating margin has been recorded at -808.85%. The firm is also showcasing profitability through returns on assets in the company’s ownership, with ROA set at -74.67%. Beta value of the stock is recorded at 1.62. Additionally, TherapeuticsMD Inc. is recording price volatility of 6.37% for the period of the last seven days and 6.35% in the last 30 days.

TherapeuticsMD Inc. (NASDAQ:TXMD) Technical Outlook

For the period of the last 50 days, TherapeuticsMD Inc. had its Raw Stochastic average set at 5.64% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 16.91%. Stochastic %K for TherapeuticsMD Inc., with the last 20 days included, was set at 11.31%, having Stochastic %D topping 7.85%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be discouraging for TherapeuticsMD Inc. stocks with recording -36.48% in metrics.

TherapeuticsMD Inc. Insider Watch:

Similarly, 95.59% of the company’s float is held by institutions – and there are 191 institutions in total holding shares of this company. The top three institutional holders of TXMD stocks are: JP Morgan Chase & Company with ownership of $72.27 million, which is approximately 19910296 of the company’s shares; FMR, LLC, holding 18620930 shares of the stock with an approximate value of $67.59 million; and Blackrock Inc., currently with more than 16518688 shares of the company valued at $59.96 million. Positions in TherapeuticsMD Inc. stocks held by institutional investors has been changing actively in the past six months, a period during which there were 13 insider purchases amounting to 555549 shares.